D. Hamlin

Samuel S. Morrison, D. Hamlin, C. M. Niver, 2017, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.

B. Miller, B. Sandmaier, J. Pagel, 2015, Blood.

for nonmyelablative allogeneic marrow grafts Bismuth-213 labeled anti-CD45 radioimmunoconjugate to condition dogs

D. Hamlin, D. Wilbur, D. Fisher, 2013 .

Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.

J. Pagel, D. Hamlin, D. Wilbur, 2013, Blood.

Selective T-cell ablation with bismuth-213–labeled anti-TCRαβ as nonmyeloablative conditioning for allogeneic canine marrow transplantation

M. Brechbiel, R. Storb, B. Sandmaier, 2003 .

Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts.

M. Brechbiel, R. Storb, B. Sandmaier, 2002, Blood.

Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment.

B. Sandmaier, J. Pagel, T. Gooley, 2016, Blood.

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.

F. Appelbaum, J. Pagel, D. Hamlin, 2011, Blood.

Radioimmunotherapy with Bismuth-213 as Conditioning for Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Dogs: A Dose Deescalation Study

M. Brechbiel, R. Storb, B. Sandmaier, 2004, Transplantation.

CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.

K. Wittrup, T. Gooley, D. Hamlin, 2018, Blood.

Glypican-3–Targeted 227Th α-Therapy Reduces Tumor Burden in an Orthotopic Xenograft Murine Model of Hepatocellular Carcinoma

R. Yeung, James O. Park, D. Hamlin, 2021, The Journal of Nuclear Medicine.

Streptavidin in antibody pretargeting. 4. Site-directed mutation provides evidence that both arginine and lysine residues are involved in kidney localization.

D. Hamlin, D. Wilbur, Yukang Lin, 2004, Bioconjugate chemistry.

Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.

F. Appelbaum, J. Pagel, D. Hamlin, 2008, Cancer research.

Streptavidin in antibody pretargeting. 5. chemical modification of recombinant streptavidin for labeling with the alpha-particle-emitting radionuclides 213Bi and 211At.

M. Brechbiel, D. Hamlin, D. Wilbur, 2008, Bioconjugate chemistry.

Investigation of a tellurium-packed column for isolation of astatine-211 from irradiated bismuth targets and demonstration of a semi-automated system

D. Hamlin, D. Wilbur, R. Wong, 2019, Scientific Reports.

α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation

B. Miller, R. Storb, B. Sandmaier, 2015, The Journal of Nuclear Medicine.

Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines.

B. Sandmaier, D. Hamlin, D. Wilbur, 2012, Bioconjugate chemistry.

Pilot Study of a 213Bismuth-Labeled Anti-CD45 mAb as a Novel Nonmyeloablative Conditioning for DLA-Haploidentical Littermate Hematopoietic Transplantation

R. Storb, B. Sandmaier, D. Hamlin, 2010, Transplantation.

Reagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatine.

B. Sandmaier, M. Thakar, J. Pagel, 2009, Bioconjugate chemistry.

Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.

R. Storb, B. Sandmaier, M. Thakar, 2009, Cancer research.

Design and evaluation of an external high‐current target for production of 211At

D. Hamlin, D. Wilbur, K. Gagnon, 2012 .

Streptavidin in antibody pretargeting. 3. Comparison of biotin binding and tissue localization of 1,2-cyclohexanedione and succinic anhydride modified recombinant streptavidin.

R. Vessella, D. Hamlin, D. Wilbur, 2002, Bioconjugate chemistry.

Streptavidin in antibody pretargeting. 2. Evaluation Of methods for decreasing localization of streptavidin to kidney while retaining its tumor binding capacity.

R. Vessella, P. Stayton, D. Hamlin, 1998, Bioconjugate chemistry.

Streptavidin in antibody pretargeting. Comparison of a recombinant streptavidin with two streptavidin mutant proteins and two commercially available streptavidin proteins.

R. Vessella, P. Stayton, J. Stray, 1998, Bioconjugate chemistry.

Evaluation of radioiodinated protein conjugates and their potential metabolites containing lysine-urea-glutamate (LuG), PEG and closo-decaborate(2-) as models for targeting astatine-211 to metastatic prostate cancer.

R. Vessella, S. Wilbur, H. Nguyen, 2020, Nuclear medicine and biology.

Reagents for astatination of biomolecules. 3. Comparison of closo-decaborate(2-) and closo-dodecaborate(2-) moieties as reactive groups for labeling with astatine-211.

D. Hamlin, D. Wilbur, M. Chyan, 2009, Bioconjugate chemistry.

Thorium chelators for Targeted Alpha Therapy: Rapid chelation of thorium-226.

D. Hamlin, D. Wilbur, M. Fassbender, 2020, Journal of labelled compounds & radiopharmaceuticals.

Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination.

R. Vessella, M. Hawthorne, D. Hamlin, 2007, Bioconjugate chemistry.

Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds.

R. Vessella, M. Hawthorne, M. Zalutsky, 2004, Bioconjugate chemistry.

A streptavidin-biotin binding system that minimizes blocking by endogenous biotin.

D. Hyre, P. Stayton, D. Hamlin, 2002, Bioconjugate chemistry.

Development of a unique bismuth (Bi-213) automated generator for use in cancer therapy.

T. Tenforde, J. Tingey, D. Hamlin, 2000 .

radioimmunotherapy of CD20-expressing lymphoma xenografts A comparative evaluation of conventional and pretargeted

Damon L. Meyer, D. Hamlin, D. Wilbur, 2013 .

Biodistribution of yttrium-90-labeled anti-CD45 antibody in a nonhuman primate model.

F. Appelbaum, K. Krohn, J. Pagel, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Oxidation of p-[125I]Iodobenzoic Acid and p-[211At]Astatobenzoic Acid Derivatives and Evaluation In Vivo

E. Corey, H. Nguyen, D. Hamlin, 2022, International journal of molecular sciences.

Biotin reagents in antibody pretargeting. 6. Synthesis and in vivo evaluation of astatinated and radioiodinated aryl- and nido-carboranyl-biotin derivatives.

R. Vessella, D. Hamlin, D. Wilbur, 2004, Bioconjugate chemistry.

CD 45 antibody for conditioning in allogeneic − astatine-211-emitter α Durable donor engraftment after radioimmunotherapy using

R. Storb, B. Sandmaier, B. Storer, 2012 .

Development Of [211At]Astatine-Based Anti-CD123 Radioimmunotherapy For Acute Leukemias and Other CD123+ Malignancies

B. Sandmaier, R. Walter, D. Hamlin, 2022, Leukemia.

Anti-CD45 Radioimmunotherapy with 90Y but Not 177Lu Is Effective Treatment in a Syngeneic Murine Leukemia Model

J. Pagel, T. Gooley, D. Hamlin, 2014, PloS one.

Selective T-cell ablation with bismuth-213-labeled anti-TCRalphabeta as nonmyeloablative conditioning for allogeneic canine marrow transplantation.

M. Brechbiel, R. Storb, B. Sandmaier, 2003, Blood.

Small-scale (sub-organ and cellular level) alpha-particle dosimetry methods using an iQID digital autoradiography imaging system

K. Vetter, B. Miller, Youngho Seo, 2022, Scientific Reports.

Synthesis and radioiodination of a nido-1,2-carboranyl derivative of 2-nitroimidazole.

G. Laramore, T. Griffin, D. Hamlin, 1994, Nuclear medicine and biology.

Preparation and evaluation of radioiodinated biotin derivatives which contain ionic charges

R. Vessella, D. Hamlin, D. Wilbur, 2001 .

Antibody fragments in tumor pretargeting. Evaluation of biotinylated Fab' colocalization with recombinant streptavidin and avidin.

R. Vessella, P. Stayton, J. Stray, 1996, Bioconjugate chemistry.

Synthesis and radioiodination of N-Boc-p-(tri-n-butylstannyl)-L-phenylalanine tetrafluorophenyl ester: preparation of a radiolabeled phenylalanine derivative for peptide synthesis.

H. Burns, D. Hamlin, D. Wilbur, 1993, Bioconjugate chemistry.

Synthesis of Highly Iodinated Icosahedral Mono- and Dicarbon Carboranes.

D. Hamlin, D. Wilbur, R. Srivastava, 1996, The Journal of organic chemistry.

Evaluation of biotin-dye conjugates for use in an HPLC assay to assess relative binding of biotin derivatives with avidin and streptavidin.

K. Gee, W. Leung, D. Hamlin, 2000, Bioconjugate chemistry.

Development of an autonomous solvent extraction system to isolate astatine-211 from dissolved cyclotron bombarded bismuth targets

D. Hamlin, D. Wilbur, M. O’Hara, 2019, Scientific Reports.

Preparation of Meta-Carborane Derivatives by Thermal Rearrangement in a Small Scale Laboratory Apparatus.

G. Laramore, T. Griffin, D. Hamlin, 1993 .

Synthesis, radioiodination, and biodistribution of some nido- and closo-monocarbon carborane derivatives.

D. Hamlin, D. Wilbur, R. Srivastava, 2004, Nuclear medicine and biology.

Hypoxia-Selective Cellular Toxicity of Carboranyl-Nitroimidazole

G. Laramore, L. Wiens, D. Hamlin, 1993 .

Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

T. Gooley, D. Hamlin, D. Wilbur, 2017, Cancer research.

The Alpha Emitter Astatine-211 Targeted to CD38 can Eradicate Multiple Myeloma in a Disseminated Disease Model.

B. Miller, B. Sandmaier, T. Gooley, 2019, Blood.

Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation.

R. Storb, B. Sandmaier, B. Storer, 2012, Blood.

(211)Astatine-Conjugated Monoclonal CD45 Antibody-Based Nonmyeloablative Conditioning for Stem Cell Gene Therapy.

B. Sandmaier, H. Kiem, D. Hamlin, 2015, Human gene therapy.

A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.

B. Wood, J. Pagel, T. Gooley, 2014, Cancer research.

Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA

B. Sandmaier, K. Wittrup, J. Pagel, 2020, Molecular Cancer Therapeutics.

Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.

K. Wittrup, T. Gooley, D. Hamlin, 2016, Cancer research.

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.

J. Pagel, D. Hamlin, D. Wilbur, 2010, Blood.

Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.

Damon L. Meyer, P. Stayton, J. Pagel, 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Quantitative single-particle digital autoradiography with α-particle emitters for targeted radionuclide therapy using the iQID camera.

Brian W. Miller, John M. Pagel, Brenda M. Sandmaier, 2015, Medical physics.

A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.

J. Pagel, T. Gooley, D. Hamlin, 2009, Blood.

Preparation and in vivo evaluation of radioiodinated closo-decaborate(2-) derivatives to identify structural components that provide low retention in tissues.

D. Hamlin, D. Wilbur, D Scott Wilbur, 2010, Nuclear medicine and biology.

Yttrium-90-Labeled Anti-Glypican 3 Radioimmunotherapy Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular Carcinoma

R. Yeung, James O. Park, H. Nguyen, 2019, Journal of oncology.

Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular Carcinoma

R. Yeung, James O. Park, H. Nguyen, 2019 .

Evaluation of a Wet Chemistry Method for Isolation of Cyclotron Produced [211At]Astatine

D. Hamlin, D. Wilbur, Ethan R Balkin, 2013 .

Glypican-3 targeted positron emission tomography detects sub-centimeter tumors in a xenograft model of hepatocellular carcinoma

James O. Park, R. Miyaoka, D. Hamlin, 2023, EJNMMI Research.

Anti-CD38 Pretargeted Radioimmunotherapy Eradicates Multiple Myeloma Xenografts In a Murine Model

B. Wood, J. Pagel, T. Gooley, 2013 .

Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma.

Damon L. Meyer, P. Stayton, D. Hamlin, 2005, Bioconjugate chemistry.

Pretargeted Radioimmunotherapy Using an Anti-CD45 Antibody-Streptavidin Conjugate and Radiolabeled DOTA-Biotin in Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation

R. Storb, B. Sandmaier, D. Maloney, 2013 .

Trifunctional conjugation reagents. Reagents that contain a biotin and a radiometal chelation moiety for application to extracorporeal affinity adsorption of radiolabeled antibodies.

M. Brechbiel, D. Hamlin, D. Wilbur, 2002, Bioconjugate chemistry.

Biotin reagents for antibody pretargeting. 5. Additional studies of biotin conjugate design to provide biotinidase stability.

D. Hamlin, D. Wilbur, P. Pathare, 2001, Bioconjugate chemistry.

Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility.

R. Vessella, P. Stayton, J. Stray, 1998, Immunotechnology : an international journal of immunological engineering.

Conventional and Pretargeted Radioimmunotherapy Using an Anti-Murine CD45 Monoclonal Antibody in a Syngeneic, Disseminated Murine Leukemia Model.

F. Appelbaum, J. Pagel, D. Hamlin, 2006 .

Anti-CD38 Pretargeted Radioimmunotherapy Demonstrates Therapeutic Efficacy In a Human Multiple Myeloma Mouse Xenograft Model

B. Wood, J. Pagel, T. Gooley, 2011 .

Development of new biotin/streptavidin reagents for pretargeting.

R. Vessella, P. Stayton, L. Klumb, 1999, Biomolecular engineering.

Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma

R. Yeung, James O. Park, R. Miyaoka, 2021, Scientific Reports.

A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD 20-expressing lymphoma xenografts

Damon L. Meyer, D. Hamlin, D. Wilbur, 2001 .

A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts.

D. Hamlin, D. Wilbur, O. Press, 2001, Blood.

α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation

B. Miller, R. Storb, B. Sandmaier, 2015, Journal of Nuclear Medicine.

A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.

J. Pagel, T. Gooley, D. Hamlin, 2009, Blood.

Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.

F. Appelbaum, J. Pagel, D. Hamlin, 2008, Cancer research.

Biotin reagents for antibody pretargeting. 3. Synthesis, radioiodination, and evaluation of biotinylated starburst dendrimers.

R L Vessella, R. Vessella, D. Hamlin, 1998, Bioconjugate chemistry.

Pre-Targeted Radioimmunotherapy Employing a Recombinant Bispecific Antibody Using a Murine Xenograft Model of Human Leukemia

K. Wittrup, J. Pagel, Chen Fang, 2014 .

TRANSPLANTATION Anti-CD45 radioimmunotherapy using 211 At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model

J. Pagel, D. Hamlin, D. Wilbur, 2013 .

211At-Labeled Anti-CD45 Antibody as a Nonmyeloablative Conditioning for Canine DLA-Haploidentical Stem Cell Transplantation.

B. Sandmaier, D. Hamlin, D. Wilbur, 2024, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[211At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignancies

B. Sandmaier, R. Walter, D. Hamlin, 2023, Leukemia & lymphoma.